Jean-Marc Verdebout
Institut Jules Bordet
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jean-Marc Verdebout.
European Respiratory Journal | 2003
Anne-Pascale Meert; Jean-Marc Verdebout; Benoît Martin; Vincent Ninane; Francesco Feoli; Jean-Paul Sculier
The 1999 World Health Organization/International Association for the Study of Lung Cancer histological classification of preneoplastic bronchial lesions has been shown to be reproducible but little is known about its biological significance. The current study evaluated the correspondence between the morphological changes of the bronchial epithelium and epidermal growth factor receptor (EGF-R) expression. Thirteen normal bronchial epithelia, 19 hyperplasia, 16 metaplasia, 10 mild dysplasia, one moderate dysplasia, 10 severe dysplasia (SD), 14 carcinoma in situ (CIS) and 11 microinvasive tumours were assessed. A global EGF-R score obtained by the sum of the positivity score plus the EGF-R staining intensity score was calculated for each lesion. A global EGF-R score of >5 was reached only in one metaplasia, in six SD, in six CIS and in six microinvasive tumours. There was no difference in EGF-R expression between normal, hyperplastic and metaplastic epithelia versus mild dysplasia or between severe dysplasia versus CIS and microinvasive tumours but there was a statistically significant difference between mild versus severe dysplasia. This study demonstrates that epidermal growth factor receptor expression rate changes with the stage of the bronchial lesion, increasing from normal epithelium to carcinoma in situ and microinvasive tumours with a statistically significant difference between mild versus severe dysplasia.
Histopathology | 2004
Anne-Pascale Meert; Francesco Feoli; Benoît Martin; Jean-Marc Verdebout; Céline Mascaux; Alain Verhest; Vincent Ninane; Jean-Paul Sculier
Aims :u2002The World Health Organization classification of bronchial intraepithelial neoplastic lesions has been shown to be reproducible. However little is known about its biological value. The aim of this study was to assess the proliferative activity of mild (MiD), moderate (MoD), severe (SD) dysplasia and carcinoma in situ (CIS) by the expression of Ki67 on biopsy specimens obtained during fluorescence bronchoscopy.
Oncology Reports | 2002
Benoît Martin; Jean-Marc Verdebout; Céline Mascaux; Marianne Paesmans; Ghizlane Rouas; Alain Verhest; Vincent Ninane; Jean-Paul Sculier
Nuclear Medicine Communications | 2003
Pierre Bourgeois; Jean-Marie Nogaret; Isabelle Veys; Dina Hertens; Jacques Dagnelie; C. Vanhaudenaerde; Jean-Marc Verdebout; Denis Larsimont
Histopathology | 2000
Jean-Louis Dargent; Jean-Marc Verdebout; Patricia Barlow; D. R. Thomas; Anne Hoorens; Ann Goossens
Anticancer Research | 2002
Céline Mascaux; Benoît Martin; Marianne Paesmans; Jean-Marc Verdebout; Alain Verhest; P Vermylen; Tom Bosschaerts; Vincent Ninane; Jean-Paul Sculier
Annales De Pathologie | 2001
David Gancberg; Michel Scourneau; Jean-Marc Verdebout; Denis Larsimont; Alain Verhest
Anticancer Research | 2006
Anne-Pascale Meert; Benoît Martin; Jean-Marc Verdebout; Francesco Feoli; Céline Mascaux; Vincent Ninane; Jean-Paul Sculier
European Respiratory Journal | 2003
Anne-Pascale Meert; Benoît Martin; Jean-Marc Verdebout; Thierry Bosschaerts; Marianne Paesmans; Vincent Ninane; Jean-Paul Sculier
3° journée des doctorants | 2003
Anne-Pascale Meert; Jean-Marc Verdebout; Benoît Martin; Vincent Ninane; Francesco Feoli; Jean-Paul Sculier